High Throughput Screening, High Content Screening, Primary and Stem Cells By Dr Richard M. Eglen Over the past decade, the use of cell-based assays has accelerated in modern drug discovery. Indeed, the majority of assays in either target validation or lead identification/optimisation all now employ cell-based technologies. Furthermore, a wide range of target classes are […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!